Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYK2 | P29597 | 3/20 | 0.58 |
| ▸ | NR3C2 | P08235 | 10/20 | 0.46 |
| ▸ | JAK2 | O60674 | 2/20 | 0.43 |
| ▸ | JAK1 | P23458 | 2/20 | 0.43 |
| ▸ | NNMT | P40261 | 3/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4701803 | 0.87 | NR3C2 (0.55) | TYK2NR3C2JAK2 | |
| SCHEMBL16840724 | 0.84 | TYK2 (0.60) | TYK2JAK2JAK1MAPTHSD17B10 | |
| SCHEMBL15880595 | 0.79 | SMARCA2 (0.61) | NR3C2MAPTHSD17B10 | |
| SCHEMBL2686515 | 0.77 | TYK2 (0.50) | TYK2JAK2JAK1MAPTHSD17B10 | |
| SCHEMBL14319175 | 0.76 | TYK2 (0.51) | TYK2JAK2JAK1AAK1 | |
| SCHEMBL31078765 | 0.75 | AR (0.52) | TYK2NR3C2JAK2MAPTHSD17B10 | |
| SCHEMBL2606609 | 0.75 | NNMT (0.56) | TYK2NNMT | |
| SCHEMBL9278345 | 0.75 | SMARCA2 (0.65) | TYK2JAK2 | |
| SCHEMBL23015807 | 0.75 | KIF11 (0.46) | TYK2NR3C2JAK2MAPTHSD17B10 | |
| SCHEMBL4860253 | 0.75 | MAPT (0.41) | NR3C2MAPTHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7375227-B2 | Quinoline derivatives | ACTELION PHARMACEUTICALS LTD. (CH) | 2008-05-20 | — | — | US | disclosed |
| US-20050043535-A1 | 4-(Piperidyl-and pyrrolidyl-alkyl-ureido)-quinolines as urotensin II receptor antagonists | ACTELION PHARMACEUTICALS LTD. (CH) | 2005-02-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050043535-A1 | 4-(Piperidyl-and pyrrolidyl-alkyl-ureido)-quinolines as urotensin II receptor antagonists | UTS2R, NTSR2, PLAUR | TYK2 2428/4885NR3C2 668/4885JAK2 2131/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.